BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
BofA/Merrill Lynch upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Buy with a price target of $35.00.
Shares of Acadia Pharmaceuticals closed at $22.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- bluebird bio (BLUE) to Offer $200M of Common Stock
- U.S. corporate bond issuance breaks records for sixth year
- BofA/Merrill Lynch Downgrades AptarGroup (ATR) to Underperform
Create E-mail Alert Related CategoriesUpgrades
Related EntitiesMerrill Lynch, Bank of America
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!